| Assessment Status |
Pre-submission consultation scheduled |
| HTA ID |
25066 |
| Drug |
Pembrolizumab |
| Brand |
Keytruda® |
| Indication |
Pembrolizumab as a monotherapy for the treatment of resectable, locally-advanced head and neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumours express PD-L1 with a CPS ≥ 1. |
| Rapid review commissioned |
10/11/2025 |
| Rapid review completed |
09/12/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab for this indication as an adjunct to the current standard of care. |
| Full HTA commissioned by the HSE |
19/12/2025 |
